Pegfilgrastim biosimilar - Fresenius Kabi
Alternative Names: INS-20; MK-6302; MSB-11455; Pegfilgrastim-fpgk - Fresenius Kabi; StimufendLatest Information Update: 20 Feb 2023
At a glance
- Originator Insmed
- Developer Fresenius Kabi
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy induced febrile neutropenia